Guanghui Gao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Guanghui Gao has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Shengxiang Ren
Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
5 shared publications - Xuefei Li
Department of Lung Cancer and Immunology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China
3 shared publications - Chao Zhao
Department of Lung Cancer and Immunology, Shanghai Pulmonary Hospital, Tongji University, Tongji University Medical School Cancer Institute, Shanghai 200433, China
2 shared publications - Chunxia Su
Department of Comprehensive Oncology Center, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China
2 shared publications - Fengying Wu
Department of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, P. R. China
2 shared publications - Xiaoxia Chen
Department of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China
2 shared publications
Latest Publications
- Open Access
- 24 September 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (10) , 2161
Dynamic Monitoring of CTCs and EVs to Predict Chemoimmunotherapy Efficacy in Lung Cancer
Background: Circulating tumor cells (CTCs), programmed cell death-ligand 1 (PD-L1) positive CTCs (PD-L1+CTCs) and extracellular vesicles (EVs) are important biomarkers for predicting treatment efficacy. This study comprehensively investigated the factors used to forecast chemoimmunotherapy efficacy in advanced lung cancer. Methods: The CellSearch system, EVAnalyzer plugin and single-cell whole-exome sequencing (WES) were used to analyze these factors. Results: It was found that CTCs were highly detectable in advanced lung cancer. The median number of baseline CTCs was significantly lower in non-small cell lung cancer (NSCLC) than small cell lung cancer (SCLC) (3 vs. 38, p < 0.0001), as were PD-L1+CTCs (1 vs. 5, p = 0.0014). PD-L1+CTCs decreasing after two treatment circles was associated with superior ORR. Baseline median EV counts were elevated in NSCLC compared with SCLC (11,700 vs 1371, p = 0.017). Patients exhibiting divergent dynamic trends between EVs and CTC/PD-L1+CTCs demonstrated better treatment response. The combination of CTCs, PD-L1+CTCs and EVs improved predictive efficacy for both NSCLC and SCLC. CTC sequencing identified multiple pathogenic somatic variants, which might affect immunotherapy efficacy. Conclusions: Serial dynamic monitoring of CTCs, PD-L1+CTCs and EVs, as well as CTC sequencing, enables the early prediction of chemoimmunotherapy response and the discovery of mechanisms that affect immunotherapy efficacy in advanced lung cancer.
- 24 September 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (10) , 2161
Open AccessDynamic Monitoring of CTCs and EVs to Predict Chemoimmunotherapy Efficacy in Lung Cancer
Background: Circulating tumor cells (CTCs), programmed cell death-ligand 1 (PD-L1) positive CTCs (PD-L1+CTCs) and extracellular vesicles (EVs) are important biomarkers for predicting treatment efficacy. This study comprehensively investigated the factors used to forecast chemoimmunotherapy efficacy in advanced lung cancer. Methods: The CellSearch system, EVAnalyzer plugin and single-cell whole-exome sequencing (WES) were used to analyze these factors. Results: It was found that CTCs were highly detectable in advanced lung cancer. The median number of baseline CTCs was significantly lower in non-small cell lung cancer (NSCLC) than small cell lung cancer (SCLC) (3 vs. 38, p < 0.0001), as were PD-L1+CTCs (1 vs. 5, p = 0.0014). PD-L1+CTCs decreasing after two treatment circles was associated with superior ORR. Baseline median EV counts were elevated in NSCLC compared with SCLC (11,700 vs 1371, p = 0.017). Patients exhibiting divergent dynamic trends between EVs and CTC/PD-L1+CTCs demonstrated better treatment response. The combination of CTCs, PD-L1+CTCs and EVs improved predictive efficacy for both NSCLC and SCLC. CTC sequencing identified multiple pathogenic somatic variants, which might affect immunotherapy efficacy. Conclusions: Serial dynamic monitoring of CTCs, PD-L1+CTCs and EVs, as well as CTC sequencing, enables the early prediction of chemoimmunotherapy response and the discovery of mechanisms that affect immunotherapy efficacy in advanced lung cancer.
- 7 June 2021
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 71 (1) , 219-228
ICI plus chemotherapy prolonged survival over ICI alone in patients with previously treated advanced NSCLC
Objectives Immune checkpoint inhibitors (ICI) monotherapy was standard of care in second-line treatment of patients with advance non-small cell lung cancer (NSCLC). This study aims to investigate the efficacy of ICI plus chemotherapy in patients with previously treated advanced NSCLC. Patients and methods An investigator-initiated trial (IIT) aiming to evaluate the efficacy and safety of ICI in combination with chemotherapy as second line and beyond for patients with advanced NSCLC was undergone at Shanghai Pulmonary Hospital (ChiCTR1900026203). Patients who received ICI monotherapy as second or later line setting during the same period were also collected as a comparator. Results From April 2018 to June 2019, 31 patients were included into this IIT study, simultaneously 51 patients treated with ICI monotherapy were selected as a comparator. ICI plus chemotherapy showed a significantly higher ORR (35.5% vs. 15.7%, p=0.039), prolonged PFS (median: 5.6 vs. 2.5 months, p = 0.013) and OS (median: NE vs. 12.6 months, p = 0.038) compared with ICI alone. In the subgroup of negative PD-L1 expression (9 patients in combination group and 12 patients in monotherapy group), ICI plus chemotherapy also had a favorable ORR (44.4% vs. 8.3%, p = 0.119), longer PFS (median: 6.5 vs 3.0 months, p < 0.05) and OS (median: NE vs. 8.2 months, p = 0.117). Meanwhile, the addition of chemotherapy did not increase immune-related adverse events. Conclusions ICI plus chemotherapy showed superior ORR, PFS and OS than ICI alone patients with previous treated advanced NSCLC. These findings warrant further investigation.
- 7 June 2021
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 71 (1) , 219-228
ICI plus chemotherapy prolonged survival over ICI alone in patients with previously treated advanced NSCLC
Objectives Immune checkpoint inhibitors (ICI) monotherapy was standard of care in second-line treatment of patients with advance non-small cell lung cancer (NSCLC). This study aims to investigate the efficacy of ICI plus chemotherapy in patients with previously treated advanced NSCLC. Patients and methods An investigator-initiated trial (IIT) aiming to evaluate the efficacy and safety of ICI in combination with chemotherapy as second line and beyond for patients with advanced NSCLC was undergone at Shanghai Pulmonary Hospital (ChiCTR1900026203). Patients who received ICI monotherapy as second or later line setting during the same period were also collected as a comparator. Results From April 2018 to June 2019, 31 patients were included into this IIT study, simultaneously 51 patients treated with ICI monotherapy were selected as a comparator. ICI plus chemotherapy showed a significantly higher ORR (35.5% vs. 15.7%, p=0.039), prolonged PFS (median: 5.6 vs. 2.5 months, p = 0.013) and OS (median: NE vs. 12.6 months, p = 0.038) compared with ICI alone. In the subgroup of negative PD-L1 expression (9 patients in combination group and 12 patients in monotherapy group), ICI plus chemotherapy also had a favorable ORR (44.4% vs. 8.3%, p = 0.119), longer PFS (median: 6.5 vs 3.0 months, p < 0.05) and OS (median: NE vs. 8.2 months, p = 0.117). Meanwhile, the addition of chemotherapy did not increase immune-related adverse events. Conclusions ICI plus chemotherapy showed superior ORR, PFS and OS than ICI alone patients with previous treated advanced NSCLC. These findings warrant further investigation.
- 1 January 2020
- Published by Elsevier in Lung Cancer
- Vol. 139, 133-139
Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC
- 1 January 2020
- Published by Elsevier in Lung Cancer
- Vol. 139, 133-139
Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC
- Open Access
- 7 March 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 1-10
Comprehensive evaluation of NT5E/CD73 expression and its prognostic significance in distinct types of cancers
CD73 is one of the critical component in the formation of immunosuppressive microenvironment in cancers. We aimed to provide an overview of the current status of CD73 expression and its relationship with clinicopathlogical features and prognosis in different cancers. PubMed, Web of Science, EMBASE and Cochrane library were searched to identify the relevant studies. CD73 expression level in distinct cancers and its relationship with clinicopathlogical characteristics and prognosis were investigated using online database. Meta-analyses were conducted using RevMan v5.0 and STATA v12.0. Fourteen publications with 2951 cases were included. The incidence of high CD73 expression was 0.50 (95% CI: 0.36–0.63). Data from Oncomine validated that median CD73 expression level in tumor tissues was markedly higher than that in normal tissues in most kinds of cancers except cecum adenocarcinoma and ovarian cancer (P < 0.05). High CD73 expression was significantly correlated with shorter overall survival (OS) in various cancers (high risk [HR] = 1.48; P < 0.05). Subgroup analysis using online database demonstrated that high CD73 expression was significantly correlated with poor OS in breast (HR = 1.23; P < 0.05) and ovarian cancer (HR = 1.14; P < 0.05), but favorable OS in lung (HR = 0.80; P < 0.05) and gastric cancer (HR = 0.71; P < 0.05). High CD73 expression was dramatically associated with lymph node metastases (OR = 2.61; P = 0.05). High CD73 expression was significantly associated with lymph node metastases and a promising prognostic factor in different types of cancers.
- 7 March 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 1-10
Open AccessComprehensive evaluation of NT5E/CD73 expression and its prognostic significance in distinct types of cancers
CD73 is one of the critical component in the formation of immunosuppressive microenvironment in cancers. We aimed to provide an overview of the current status of CD73 expression and its relationship with clinicopathlogical features and prognosis in different cancers. PubMed, Web of Science, EMBASE and Cochrane library were searched to identify the relevant studies. CD73 expression level in distinct cancers and its relationship with clinicopathlogical characteristics and prognosis were investigated using online database. Meta-analyses were conducted using RevMan v5.0 and STATA v12.0. Fourteen publications with 2951 cases were included. The incidence of high CD73 expression was 0.50 (95% CI: 0.36–0.63). Data from Oncomine validated that median CD73 expression level in tumor tissues was markedly higher than that in normal tissues in most kinds of cancers except cecum adenocarcinoma and ovarian cancer (P < 0.05). High CD73 expression was significantly correlated with shorter overall survival (OS) in various cancers (high risk [HR] = 1.48; P < 0.05). Subgroup analysis using online database demonstrated that high CD73 expression was significantly correlated with poor OS in breast (HR = 1.23; P < 0.05) and ovarian cancer (HR = 1.14; P < 0.05), but favorable OS in lung (HR = 0.80; P < 0.05) and gastric cancer (HR = 0.71; P < 0.05). High CD73 expression was dramatically associated with lymph node metastases (OR = 2.61; P = 0.05). High CD73 expression was significantly associated with lymph node metastases and a promising prognostic factor in different types of cancers.
- Open Access
- 6 February 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 148
Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: a systematic review and meta-analysis
Although EGFR-TKI is the preferred treatment for NSCLC patients with sensitive mutations, subsequent drug resistance is almost inevitable. The specific mechanisms of EGFR-TKI drug resistance can be identified through repeat biopsy. To better understand the clinical characteristics of TKI resistance in NSCLC patients, we retrospectively reviewed studies of acquired TKI drug resistance using repeat biopsy from the last decade. The relevant literature was retrieved from January 2005 to August 2015 in the databases Medline and Embase. The search terms were NSCLC or non-small cell lung cancer and T790 M. A total of 478 patients with NSCLC tested by repeated biopsy were confirmed to have acquired TKI resistance. Analysis indicated that 240 patients (50.21%) of the 478 patients with acquired TKI drug resistance had the T790 M mutation. The detection rate of T790 M in different repeat biopsy sites was also different, with the highest positive rate in the lymph nodes (60%) and the lowest detection rate in cerebrospinal fluid (less than 5%). In addition, patients with T790 M had longer overall survival compared to those without the mutation (P < 0.05). Of the 240 patients with T790 M mutations, 213 patients showed results consistent with the mutation analysis before TKI treatment, and the rate of patients with the L858R point mutation along with the T790 M mutation was lower than that of patients with the exon 19 deletion (36.42% to 58.30%). T790 M occurred more frequently in patients with the exon 19 deletion than in those with exon 21 L858R, which gave the survival benefit of the T790 M mutation and may explain why patients with the exon 19 deletion had an improved overall survival.
- 6 February 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 148
Open AccessFrequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: a systematic review and meta-analysis
Although EGFR-TKI is the preferred treatment for NSCLC patients with sensitive mutations, subsequent drug resistance is almost inevitable. The specific mechanisms of EGFR-TKI drug resistance can be identified through repeat biopsy. To better understand the clinical characteristics of TKI resistance in NSCLC patients, we retrospectively reviewed studies of acquired TKI drug resistance using repeat biopsy from the last decade. The relevant literature was retrieved from January 2005 to August 2015 in the databases Medline and Embase. The search terms were NSCLC or non-small cell lung cancer and T790 M. A total of 478 patients with NSCLC tested by repeated biopsy were confirmed to have acquired TKI resistance. Analysis indicated that 240 patients (50.21%) of the 478 patients with acquired TKI drug resistance had the T790 M mutation. The detection rate of T790 M in different repeat biopsy sites was also different, with the highest positive rate in the lymph nodes (60%) and the lowest detection rate in cerebrospinal fluid (less than 5%). In addition, patients with T790 M had longer overall survival compared to those without the mutation (P < 0.05). Of the 240 patients with T790 M mutations, 213 patients showed results consistent with the mutation analysis before TKI treatment, and the rate of patients with the L858R point mutation along with the T790 M mutation was lower than that of patients with the exon 19 deletion (36.42% to 58.30%). T790 M occurred more frequently in patients with the exon 19 deletion than in those with exon 21 L858R, which gave the survival benefit of the T790 M mutation and may explain why patients with the exon 19 deletion had an improved overall survival.
- 9 January 2012
- Published by Elsevier in Lung Cancer
- Vol. 76 (3) , 380-386
A meta-analysis of paclitaxel-based chemotherapies administered once every week compared with once every 3 weeks first-line treatment of advanced non-small-cell lung cancer
- 9 January 2012
- Published by Elsevier in Lung Cancer
- Vol. 76 (3) , 380-386
A meta-analysis of paclitaxel-based chemotherapies administered once every week compared with once every 3 weeks first-line treatment of advanced non-small-cell lung cancer